Microcap Ledger Insight Molecular Diagnostics Inc. $IMDX
Facts as of . Built from SEC filings and our own data. Small caps move fast; check the latest filings.
Snapshot
- Exchange
- Nasdaq Capital Market
- Sector
- In Vitro & In Vivo Diagnostic Substances
- Headquarters
- Nashville, TN
- Fiscal year end
- December 31
- Shares outstanding
- 32,724,284 [10-Q 2026-08-10]
What the company doesAI summary of filing
Insight Molecular Diagnostics Inc. (iMDx) develops molecular diagnostic tests, primarily for transplant organ rejection monitoring and oncology applications. The company operates a CLIA-certified laboratory in Franklin, Tennessee that provides laboratory-developed tests (LDTs) for Medicare reimbursement, and is developing kitted research-use-only (RUO) and in-vitro diagnostic (IVD) products for in-house testing by hospitals and laboratories. iMDx generates revenue from its GraftAssureCore LDT service, which received Medicare coverage and reimbursement in August 2023 at $2,753 per result as of May 2025, and sold its first GraftAssureIQ RUO kits in May 2025. The company also performs assay development and clinical testing services for third parties through its Laboratory Services operations. [10-K 2026-03-26]
Financial health
| Period | Revenue | Net income | Operating cash flow | Cash | Filing |
|---|---|---|---|---|---|
| 6 months to Jun 2026 | $271.0K | −$15.55M | −$16.91M | $17.76M | [10-Q 2026-08-10] |
| FY ended Dec 2025 | $4.05M | −$50.2K | −$22.18M | $11.58M | [10-K 2026-03-26] |
| FY ended Dec 2024 | $1.88M | −$60.7K | −$20.69M | $8.64M | [10-K 2026-03-26] |
- Quarterly cash burn
- −$8.45M
- Cash runway Estimate
- ~6.3 months
Capital structure and dilution
| Date | Shares outstanding | Filing |
|---|---|---|
| 2024-11-05 | 16,835,247 | [10-Q 2024-11-12] |
| 2025-03-17 | 28,599,285 | [10-K 2025-03-24] |
| 2025-05-05 | 28,599,285 | [10-Q 2025-05-12] |
| 2025-08-04 | 28,619,749 | [10-Q 2025-08-11] |
| 2025-11-03 | 28,664,437 | [10-Q 2025-11-10] |
| 2026-03-19 | 32,167,978 | [10-K 2026-03-26] |
| 2026-05-04 | 32,290,167 | [10-Q 2026-05-13] |
| 2026-08-03 | 32,724,284 | [10-Q 2026-08-10] |
- Shelf registration
- S-1 filed 2025-03-28; declared effective 2025-04-07 [S-1 2025-03-28]
Listing status
Current status: No Form 8-K Item 3.01 (listing notice) filings in the last 24 months, as of 2026-10-11.
Who owns it
| Date | Insider | Type | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-07-01 | Silverman Lou | other | 7,700 | $5.69 | [4 2026-07-06] |
| 2026-07-01 | Last Andrew J. | other | 7,700 | $5.69 | [4 2026-07-06] |
| 2026-07-01 | Arno Andrew | other | 12,100 | $5.69 | [4 2026-07-06] |
| 2026-06-11 | Silverman Lou | grant | 26,943 | — | [4 2026-06-15] |
| 2026-06-11 | Last Andrew J. | grant | 26,943 | — | [4 2026-06-15] |
| 2026-06-11 | Arno Andrew | grant | 32,331 | — | [4 2026-06-15] |
| 2026-04-27 | Broadwood Partners, L.P. | buy | 250,923 | $3.64 | [4 2026-04-27] |
| 2026-04-24 | Broadwood Partners, L.P. | buy | 38,880 | $3.53 | [4 2026-04-27] |
| 2026-04-23 | Broadwood Partners, L.P. | buy | 280,381 | $3.50 | [4 2026-04-27] |
| 2026-04-20 | Broadwood Partners, L.P. | buy | 40,690 | $3.88 | [4 2026-04-20] |
| 2026-04-17 | Broadwood Partners, L.P. | buy | 40,114 | $3.57 | [4 2026-04-20] |
| 2026-04-16 | Broadwood Partners, L.P. | buy | 102,057 | $3.45 | [4 2026-04-20] |
Catalysts and calendar
| Date | Type | Title |
|---|---|---|
| 2026-09-21 | 8-K | Material agreement entered |
| 2026-08-10 | 10-Q | Quarterly report |
| 2026-08-10 | 8-K | Results of operations; Regulation FD disclosure; Other events |
| 2026-06-17 | 8-K | Director or officer change; Shareholder vote results |
| 2026-05-13 | 10-Q | Quarterly report |
| 2026-05-13 | 8-K | Results of operations |
| 2026-05-13 | 8-K | Other events |
| 2026-04-30 | DEF 14A | Proxy statement |
| 2026-04-30 | 8-K | Other events |
| 2026-04-27 | 13D/A | Beneficial ownership report (5%+ holder) |
| 2026-03-26 | 10-K | Annual report |
| 2026-03-26 | 8-K | Results of operations |
Alerts for $IMDX
Email me when Insight Molecular Diagnostics Inc. files an offering, gets a deficiency notice, or moves sharply.
Facts as of . Small caps move fast; check the latest filings.